The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Open accessAbstract
There are a number of reports in literature data on the long-term outcomes of patients with multiple myeloma treated with high-dose therapy and autologous stem cell transplantation (HDT/SCT). While in general these data support the association between maximal tumor response and overall survival or progression-free survival after HDT/SCT, some trials have failed to find such correlation and there is no recent comprehensive literature analysis of this issue. We, therefore, performed a comprehensive literature review to identify prospective and retrospective studies on HDT/SCT in frontline multiple myeloma in which long-term outcomes were reported according to best tumor response observed. Following a prospectively defined search strategy we identified 21 studies (10 prospective and 11 retrospective studies) in which outcomes of 4,990 HDT/SCT patients according to their best tumor response were reported. The majority of these studies indicated a correlation between maximal response during or after HDT/SCT and long-term outcomes (overall survival and event-free/progression-free survival). The conclusions in individual studies report on the association between maximal response following induction therapy and long-term outcomes were more heterogeneous, possibly due to the low rate of complete response after standard induction therapy in each individual study. We, therefore, performed two types of meta-analyses, one based on the p-values reported for these associations in the individual studies, and one based on the primary response and outcome data provided in the individual studies. Both meta-analyses indicated highly significant associations between maximal response (complete response/near complete response/very good partial response) during or after HDT/SCT and long-term outcomes (overall survival and event-free/progression-free survival). Both meta-analyses also provided evidence of highly significant associations between maximal response following induction therapy and long-term outcomes (overall survival and event-free/progression-free survival).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 2×
“In the IFM 94-02 trial, patients who had already obtained a CR/VGPR after one transplant (CR1/VGPR1) did not benefit significantly from a second transplant in terms of overall survival.(2) The importance of CR or VGPR following HDT was confirmed in most, but not all, retrospective series (Table 2).”
BackgroundMethodThe Medical Review Article: State of the Science
MULROW, C. D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-3-485 · Cited by 856
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053583 · Cited by 739
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Systematic Reviews: Checklists for review articles
Oxman, A. D. (1994) · BMJ · doi:10.1136/bmj.309.6955.648 · Cited by 480
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
Walker, R., Barlogie, B., Haessler, J., Tricot, G., Anaissie, E., Shaughnessy, J. D., Epstein, J., van Hemert, R., Erdem, E., Hoering, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5803 · Cited by 417
Fermand, J.-P., Katsahian, S., Divine, M., Leblond, V., Dreyfus, F., Macro, M., Arnulf, B., Royer, B., Mariette, X., Pertuiset, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0551 · Cited by 399
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
Alexanian, R., Weber, D., Giralt, S., Dimopoulos, M. A., Delasalle, K. B., Smith, T., & Champlin, R. E. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703035 · Cited by 135
Durie, B. G. M., Jacobson, J. L., Barlogie, B., & Crowley, J. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.111 · Cited by 132
Davies, F. E., Forsyth, P. D., Rawstron, A. C., Owen, R. G., Pratt, G., Evans, P., Richards, S. J., Drayson, M. T., Smith, G., Selby, P. J., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02530.x · Cited by 111
O’Shea, D., Giles, C. M., Terpos, E., Perz, J. B., Politou, M., Sana, V., Naresh, K. N., Lampert, I. A., Samson, D., Narat, S., et al. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705307 · Cited by 108
Lahuerta, J. J., Martínez‐López, J., de la Serna, J., Bladé, J., Grande, C., Alegre, A. M., Vázquez, L., García‐Laraña, J., Sureda, A. M., de la Rubia, J., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02012.x · Cited by 107
Methodologic Guidelines for Review Papers
Weed, D. L. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.6 · Cited by 75
Lenhoff, S., Hjorth, M., Turesson, I., Westin, J., Gimsing, P., Wislöff, F., Ahlberg, L., Carlson, K. E., Christiansen, I., Dahl, I. M. S., et al. (2006) · PubMed · Cited by 72
Terpos, E., Apperley, J. F., Samson, D., Giles, C. M., Crawley, C. R., Kanfer, E., Olavarría, E., Goldman, J. M., & Rahemtulla, A. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703818 · Cited by 69
Nadal, E., Giné, E., Bladé, J., Esteve, J., Rosiñol, L., Fernández‐Avilés, F., Marı́n, P., Martı́nez, C., Rovira, M., Urbano-Ispizúa, Á., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704313 · Cited by 60
Mouse plasmacytoid dendritic cells derive exclusively from estrogen-resistant myeloid progenitors
Harman, B. C., Miller, J. P., Nikbakht, N., Gerstein, R. M., & Allman, D. (2006) · Blood · doi:10.1182/blood-2005-11-4545 · Cited by 57
Randomized trial experience of the Intergroupe Francophone du My[eacute]lome
Attal, M., & Harousseau, J. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90014-9 · Cited by 51
Bladé, J., Esteve, J., Rives, S., Martínez, C., Rovira, M., Urbano-Ispizúa, Á., Marı́n, P., Carreras, E., & Montserrat, E. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702622 · Cited by 50
Alvares, C. L., Davies, F. E., Horton, C., Patel, G. W., Powles, R., Sirohi, B., Zuha, R., Gatt, A., Saso, R. M., Treleaven, J. G., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05514.x · Cited by 49
Majolino, I., Vignetti, M., Meloni, G., Vegna, M. L., Scimè, R., Tringali, S., Amaddii, G., Coser, P., Tribalto, M., Raimondi, R., et al. (1999) · PubMed · Cited by 37
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Galli, M., Nicolucci, A., Valentini, M., Belfiglio, M., Delaini, F., Crippa, C., Barbui, A. M., Giussani, U., Rambaldi, A., & Barbui, T. (2005) · PubMed · Cited by 18
Complete response in myeloma: a Trojan horse?
Barlogie, B., & Tricot, G. J. K. (2006) · Blood · doi:10.1182/blood-2006-07-034538 · Cited by 14
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M. T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 819
Metadata
- Authors
- van de Velde, H. J. K., Liu, X., Chen, G., Cakana, A., Deraedt, W., & Bayssas, M.
- Venue
- Haematologica
- Published
- 2007-10-01
- Volume
- 92
- Issue
- 10
- Pages
- 1399-1406
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2153596485
- Cited by
- 283
- References
- 29
- FWCI
- 11.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.